Completed OBSERVATIONAL NCT01080573

Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis (AIMS)

A Questionnaire Based Survey to Identify Issues With Patient Compliance and to Develop Solutions to Improve Rebif Compliance and Improve Patient Outcomes

Sponsor: Merck KGaA, Darmstadt, Germany

Conditions Multiple Sclerosis

Updated 7 times since 2017 Last updated: Jul 30, 2014 Started: Jan 31, 2007 Primary completion: Apr 30, 2011 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Multiple Sclerosis and is currently completed. Merck KGaA, Darmstadt, Germany leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jan 2019 — Jan 2021 [monthly]

Completed
Jun 2018 — Jan 2019 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck KGaA, Darmstadt, Germany

Data source: Merck KGaA, Darmstadt, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Harlow, United Kingdom